Mesoblast Net Income From Continuing Ops from 2010 to 2025

MESO Stock  USD 12.11  1.19  8.95%   
Mesoblast Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -83.1 M. During the period from 2010 to 2025, Mesoblast Net Loss quarterly data regression pattern had sample variance of 561 T and median of (77,940,000). View All Fundamentals
 
Net Loss  
First Reported
2014-06-30
Previous Quarter
-18.6 M
Current Value
-21.9 M
Quarterly Volatility
22.1 M
 
Yuan Drop
 
Covid
Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 24.9 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 122, Dividend Yield of 0.0 or PTB Ratio of 1.5. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Latest Mesoblast's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Mesoblast over the last few years. It is Mesoblast's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mesoblast's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Mesoblast Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(75,289,551)
Geometric Mean65,133,808
Coefficient Of Variation(31.46)
Mean Deviation13,895,263
Median(77,940,000)
Standard Deviation23,684,936
Sample Variance561T
Range94.7M
R-Value(0.25)
Mean Square Error562.9T
R-Squared0.06
Significance0.35
Slope(1,252,605)
Total Sum of Squares8414.6T

Mesoblast Net Income From Continuing Ops History

2025-83.1 M
2024-79.2 M
2023-88 M
2022-81.9 M
2021-91.3 M
2020-98.8 M
2019-77.9 M

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-79.2 M-83.1 M
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.